Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-29,504
Closed -$2.23M 669
2026
Q1
$2.23M Sell
29,504
-1,415
-5% -$106K 0.01% 443
2025
Q4
$2.3M Sell
30,919
-8,061
-21% -$589K 0.01% 448
2025
Q3
$2.63M Buy
38,980
+4,670
+14% +$310K 0.02% 438
2025
Q2
$2.24M Sell
34,310
-500
-1% -$30K 0.02% 450
2025
Q1
$2.15M Buy
34,810
+4,382
+14% +$290K 0.02% 444
2024
Q4
$2.19M Buy
30,428
+5,671
+23% +$443K 0.02% 431
2024
Q3
$2.02M Buy
24,757
+1,072
+5% +$85.7K 0.02% 435
2024
Q2
$1.76M Buy
23,685
+8,840
+60% +$663K 0.01% 426
2024
Q1
$1.16M Buy
14,845
+12,074
+436% +$898K 0.01% 452
2023
Q4
$198K Sell
2,771
-938
-25% -$65.3K ﹤0.01% 518
2023
Q3
$257K Sell
3,709
-459
-11% -$34.7K ﹤0.01% 420
2023
Q2
$337K Buy
+4,168
New +$341K ﹤0.01% 371

Other funds holding HOLX

UniSuper Management's HOLX Position: Q2 2026 in Review

UniSuper Management sold out of Hologic (HOLX) in Q2 2026, closing a stake of 29,504 shares — an estimated $2.23M sold.

UniSuper Management first reported a position in HOLX in Q2 2023 and held it in 12 quarters. The position peaked at $2.63M in Q3 2025. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • UniSuper Management reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • UniSuper Management sold 29,504 Hologic shares in Q2 2026, an estimated $2.23M.
  • UniSuper Management first reported a position in Hologic in Q2 2023 and held it in 12 quarters.
  • UniSuper Management's Hologic position peaked at $2.63M in Q3 2025.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.